Helping you to achieve key decision milestones through deep scientific insights, innovation and collaboration.
Learn More
Enabling you to successfully develop and de-risk your preclinical candidates for a smooth transition to the clinic.
Learn More
Empowering your drug discovery and development with integrated data services, machine learning and generative AI.
Learn MoreSupporting you with integrated, tailored solutions at every step of your drug discovery and development journey.
Nuvisan is the unique CRO/CDMO with extensive pharma experience and industry-leading scientific expertise, providing highest-quality end-to-end solutions. From enabling target understanding to helping get innovative medicines to the patients who need them, we provide support that streamlines and accelerates drug discovery and development.
Explore or search our library of brochures to find out how our solutions drive drug discovery and development.
Learn More
Read what our clients are saying about how partnering with Nuvisan supports them on their scientific journey.
Learn More.jpg)
Experience engaging, in-depth looks at how our services, solutions and expertise advance projects to enable breakthrough therapies.
Learn More
June 27, 2024
The global leader in testing, ALS Limited acquired Nuvisan on April 1, 2024, integrating advanced drug discovery, preclinical and clinical development capabilities into its growing portfolio. With ALS' commitment to high-quality and personalized solutions spanning from drug discovery to post-commercialization, this strategic acquisition presents specific opportunities for our customers.
Learn more
Contact Us
Procurar
